Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
about
Acute effects of cinacalcet on arterial stiffness and ventricular function in hemodialysis patients: A randomized double-blinded crossover study.Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy.Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsLC-MS/MS determination of cinacalcet enantiomers in rat plasma on Chirobiotic V column in polar ionic mode: application to a pharmacokinetic study.Comparison of AMG 416 and cinacalcet in rodent models of uremiaParathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort studyAn open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.Hypercalcemia in pregnancy - a multifaceted challenge: case reports and literature review.Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study.Clinical utilization of cinacalcet in hypercalcemic conditions.Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemoCinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses.
P2860
Q33760506-1B94100B-8C5A-493D-A778-B578AC1B2E42Q34002025-93C54F9D-E569-4A68-8D40-C289F4380A85Q34385273-D639AA1A-4C60-4D0B-B3CB-F6C97E8A126FQ35166456-CA54EE96-2F14-41A5-999D-9EAC31A5944EQ35177929-0186EF21-7B0E-4DE6-A4C1-C0446DDF74FAQ35247578-5A07127A-F32D-460A-9FEB-F57F87B51D86Q36173980-623CAE17-6C70-422A-A14D-310DA907FD7AQ37095019-1C8C5788-1C72-471D-AC7A-E3EB0A206C70Q37319373-068C6CDB-C039-4D98-97EA-FAFD2054C258Q37638757-58977CD0-9A26-476A-8607-BCFE1C568BFBQ37848439-C3F27A46-A49B-47F5-ACE0-3193D38A5BA1Q37862353-759584DD-9C0C-4010-85F8-ED91872FB571Q38085702-A2BA4CE8-4994-4361-94B2-E21217E31709Q39037214-99976840-0DD1-4F1F-875E-6A1BDFE6757BQ39259222-E81DA2B3-A7B4-4E17-971A-097169D78690Q52722043-CDC43EAE-BF11-4596-B89B-F64FB6871FBBQ55420614-CF8C02A5-71FB-4DF2-BCD6-6B028E22E701
P2860
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@nl
type
label
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@nl
prefLabel
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@nl
P1476
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
P2093
Desmond Padhi
Robert Harris
P304
P356
10.2165/00003088-200948050-00002
P577
2009-01-01T00:00:00Z
P6179
1031573244